痛風治療薬の市場規模、シェア、動向分析レポート：薬効クラス別（NSAIDs、コルチコステロイド、コルヒチン）、疾患別（急性、慢性）、流通チャネル別、地域別、セグメント予測：2023年～2030年

痛風治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、痛風治療薬の世界市場規模は2030年までに41億3,000万米ドルに達し、2023年から2030年までのCAGRは6.25%で拡大すると予測されています。

市場開拓の背景には、世界の疾病負担の増加、人々の認識を広めるための政府機関や民間団体による取り組み、この分野における新規治療法の最近の開発などがあります。さらに、臨床パイプライン医薬品の数が増加していることも、有利な市場成長機会をもたらしています。

世界では痛風の有病率が増加しており、これが市場成長を促進する重要な要因となっています。例えば、Elsevier社の論文によると、2021年にオーストラリアでは痛風の有病率が1.5%から2.9%と報告されています。同様に、2021年には、カナダと英国はそれぞれ約4％と2.33％の疾患症例の増加を報告しています。高い有病率は、高齢者人口の増加、アルコールや果糖の摂取などの不適切な食生活、座りがちなライフスタイルの増加、腎機能障害、心血管疾患、糖尿病などの併存疾患によってさらに裏付けられています。

強固な臨床試験パイプラインと期待される新治療薬の上市は、予測期間中の市場成長を後押しすると予想されます。現在、Jiangsu HengRui Medicine Co, Ltd.のSHR4640のような新薬候補が痛風の治療薬として第3相臨床試験段階にあります。同様に、2023年3月、Selecta Biosciences, Inc.は、SEL-212の第3相DISSOLVE I &IIプラセボ対照無作為化臨床試験の良好な結果を発表しました。SEL-212は慢性難治性痛風を適応症としています。

主要企業は、共同研究、M&A、契約、金融投資などの戦略的な取り組みを行っており、市場の成長を促進しています。例えば、2021年6月、Horizon Therapeutics plcはArrowhead Pharmaceuticalsと提携し、制御不能な痛風の治療薬となりうるRNAi治療薬を開発しました。2022年7月、同社は制御不能な痛風患者に対するKrystexxaの拡大承認をFDAから取得しました。この薬は免疫療法や化学療法薬のメトトレキサートと併用されます。

さらに、2023年3月、Horizon社は、全国腎臓月間キャンペーン"Weed it G'out"を実施しました。このキャンペーンでは、花と雑草を使って、尿酸が腎臓に及ぼす影響との相関関係を表現しています。このキャンペーンは、痛風に対する認識を高め、痛風を深刻に受け止め、専門医に相談するよう促すことを目的としています。

痛風治療薬市場レポートハイライト

• 非ステロイド性抗炎症薬（NSAIDs）セグメントは、処方率の高さ、コストの低さ、市場における存在感の強さにより、2022年の市場シェアで最大を占めました。
• 疾患別では、慢性疾患と比較して患者数が多いことから、急性疾患セグメントが2022年の市場シェア全体の65.77%を占める
• 2022年には、小売薬局がこの領域で最も高いセグメントシェアを占めました。しかし、予測期間中はオンライン薬局が最も急成長する見込み
• 痛風患者の増加、病気治療に対する個人の意識の高さ、同地域のヘルスケアへのアクセスの良さなどの要因により、2022年の世界市場は北米が支配的でした。
• 同分野の主要企業には、GlaxoSmithKline plc、Takeda Pharmaceutical Company Ltd.、Regeneron Pharmaceuticals Inc、Novartis AG、AstraZeneca plc、Merck &Co.Inc.、Teijin Ltd.、Horizon Pharma plc、Zydus Groupなどです。

目次

第1章 調査手法と範囲

• 市場セグメンテーション
  • 推定・予測のタイムライン
• 市場の定義
• 調査手法
• 情報調達
  • 購入したデータベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の形成と検証
• モデル詳細
  • 商品フロー分析
• 地域市場：CAGRの計算
• 調査の仮定
• 二次情報のリスト
• 略語のリスト
• 目的

第2章 エグゼクティブサマリー

• 市場スナップショット
• 薬剤クラスと病状セグメントのスナップショット
• 流通チャネルセグメントのスナップショット
• 競合情勢のスナップショット

第3章 世界の痛風治療薬市場の変数、動向、および範囲

• 痛風治療薬市場系統の見通し
  • 親市場の見通し
• 普及と成長の見通しのマッピング
• 規制の枠組み
• 市場促進要因分析
  • 痛風の有病率の上昇
  • 強力な研究開発パイプライン別高度で新しい治療法
  • 人々の意識の高まり
• 市場抑制要因分析
  • 発展途上国および低開発国における病気の診断の遅れ
• ポーターのファイブフォース分析
• パイプライン分析

第4章 痛風治療薬市場：セグメント分析、薬剤クラス別、2018年～2030年（100万米ドル）

• 世界の痛風治療薬市場：薬剤クラスの変動分析
• NSAIDs
  • NSAIDs市場推計・予測、2018～2030年（100万米ドル）
• コルチコステロイド
  • コルチコステロイド市場推計・予測、2018-2030（100万米ドル）
• コルヒチン
  • コルヒチン市場推計・予測、2018-2030（100万米ドル）
• 尿酸降下剤
  • 尿酸降下剤市場推計・予測、2018年から2030年（100万米ドル）
• その他
  • その他の市場推計・予測、2018-2030（100万米ドル）

第5章 痛風治療薬：セグメント分析、疾患別、2018～2030年（100万米ドル）

• 世界の痛風治療薬市場：病状変動分析
• 急性痛風
  • 急性痛風市場推計・予測、2018年から2030年（100万米ドル）
• 慢性痛風
  • 慢性痛風市場推計・予測、2018年から2030年（100万米ドル）

第6章 痛風治療薬市場：セグメント分析、流通チャネル別、2018年～2030年（100万米ドル）

• 世界の痛風治療薬市場：流通チャネルの変動分析
• 病院薬局
  • 病院薬局市場推計・予測、2018年から2030年（100万米ドル）
• 小売薬局
  • 小売薬局市場推計・予測、2018-2030（100万米ドル）
• オンライン薬局
  • オンライン薬局市場推計・予測、2018～2030年（100万米ドル）

第7章 痛風治療薬市場：セグメント分析、地域別、2018～2030年（100万米ドル）

• 痛風治療薬市場：地域変動分析
  • 定義と範囲
• 北米
  • 北米、SWOT分析
  • 米国
  • カナダ
• 欧州
  • 欧州、SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • スウェーデン
  • デンマーク
  • ノルウェー
• アジア太平洋地域
  • アジア太平洋、SWOT分析
  • インド
  • 中国
  • 日本
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ、SWOT分析
  • メキシコ
  • ブラジル
  • アルゼンチン
• MEA
  • 中東とアフリカ、SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 公開会社
  • 企業の市況分析
  • 競合ダッシュボード分析
  • 戦略的枠組み
• 非公開会社
  • 主要な新興企業/テクノロジーディスラプター/イノベーターのリスト
  • 地域ネットワークマップ
• 企業プロファイル
  • Takeda Pharmaceutical Company Ltd.
  • Novartis Ag
  • Regeneron Pharmaceuticals Inc.
  • Astrazeneca Plc
  • Horizon Therapeutics Plc
  • Merck &Co. Inc
  • Zydus Group
  • Teijin Ltd
  • Glaxosmithkline Plc

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 List of Parameters
• Table 4 List of Distributors
• Table 5 Global Gout Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 6 Global Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 7 Global Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 8 Global Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 9 North America Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 10 North America Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 11 North America Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 12 North America Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 14 U.S. Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 15 U.S. Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Canada Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 17 Canada Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 18 Canada Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Europe Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 20 Europe Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 21 Europe Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 22 Europe Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 Germany Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 24 Germany Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 25 Germany Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 UK Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 27 UK Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 28 UK Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 France Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 30 France Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 31 France Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 33 Italy Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 34 Italy Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Spain Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 36 Spain Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 37 Spain Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Denmark Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 39 Denmark Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 40 Denmark Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Sweden Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 42 Sweden Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 43 Sweden Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Norway Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 45 Norway Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 46 Norway Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Japan Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 52 Japan Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 53 Japan Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 China Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 55 China Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 56 China Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 India Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 58 India Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 59 India Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 South Korea Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 61 South Korea Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 62 South Korea Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Australia Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 64 Australia Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 65 Australia Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Thailand Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 67 Thailand Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 68 Thailand Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Latin America Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 70 Latin America Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 71 Latin America Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 72 Latin America Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Brazil Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 74 Brazil Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 75 Brazil Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Mexico Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 77 Mexico Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 78 Mexico Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Argentina Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 80 Argentina Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 81 Argentina Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 85 Middle East & Africa Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 South Africa Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 90 South Africa Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 91 South Africa Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 UAE Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 93 UAE Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 94 UAE Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 95 Kuwait Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 96 Kuwait Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 97 Kuwait Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & Forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market summary
• Fig. 8 Market trends & outlook
• Fig. 9 Market segmentation & scope
• Fig. 10 Market driver relevance analysis (Current & future impact)
• Fig. 11 Market restraint relevance analysis (Current & future impact)
• Fig. 12 Penetration & growth prospect mapping
• Fig. 13 Gout therapeutics market - PESTLE analysis
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Gout therapeutics market outlook key takeaways
• Fig. 16 Gout therapeutics market: Drug class movement analysis
• Fig. 17 Global gout therapeutics market, by drug class, 2018 - 2030 (USD Million)
• Fig. 18 Global gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 19 Global NSAIDs market, 2018 - 2030 (USD Million)
• Fig. 20 Global corticosteroids market, 2018 - 2030 (USD Million)
• Fig. 21 Global colchicine market, 2018 - 2030 (USD Million)
• Fig. 22 Global urate-lowering agents market, 2018 - 2030 (USD Million)
• Fig. 23 Global gout therapeutics market: Disease condition movement analysis
• Fig. 24 Global gout therapeutics market, by disease condition, 2018 - 2030 (USD Million)
• Fig. 25 Global acute gout market, 2018 - 2030 (USD Million)
• Fig. 26 Global chronic gout market, 2018 - 2030 (USD Million)
• Fig. 27 Global gout therapeutics market: Distribution Channel movement analysis
• Fig. 28 Global gout therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Fig. 29 Global retail pharmacy market, 2018 - 2030 (USD Million)
• Fig. 30 Global hospital pharmacy market, 2018 - 2030 (USD Million)
• Fig. 31 Global online pharmacy market, 2018 - 2030 (USD Million)
• Fig. 32 Regional market: Key takeaways
• Fig. 33 Gout therapeutics market regional outlook, 2018 & 2030
• Fig. 34 North America gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 35 U.S. gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 36 Canada gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 37 Europe gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 38 Germany gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 39 UK gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 40 France gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 41 Italy gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 42 Spain gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 43 Denmark gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 44 Sweden gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 45 Norway gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 46 Asia Pacific gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 47 Japan gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 48 China gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 49 India gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 50 South Korea gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 51 Australia gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 52 Thailand gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 53 Latin America gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 54 Brazil gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 55 Mexico gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 56 Argentina gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 57 Middle East Africa gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 58 South Africa gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 59 Saudi Arabia gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 60 UAE gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 61 Kuwait gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 62 Strategy frameworks

Gout Therapeutics Market Growth & Trends

The global gout therapeutics market size is expected to reach USD 4.13 billion by 2030 and expand at a CAGR of 6.25% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights

• NSAIDs segment accounted for the largest share of the market in 2022 due to the high prescription rate, low cost, and strong presence in the market.
• Based on disease condition, the acute condition segment held 65.77% of the total market share in 2022, owing to a high patient pool compared to the chronic condition
• In 2022, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
• North America dominated the global market in 2022 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region
• Some key players in the space include GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd.; Regeneron Pharmaceuticals Inc; Novartis AG; AstraZeneca plc; Merck & Co. Inc.; Teijin Ltd.; and Horizon Pharma plc; Zydus Group and others

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Market Definitions
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 Secondary Sources
  • 1.4.3 Primary Research
  • 1.4.4 Details Of Primary Research
• 1.5 Information Or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
    • 1.7.1.1 Approach 1: Commodity Flow Approach
    • 1.7.1.2 Approach 2: Country-Wise Market Estimation Using The Bottom-Up Approach
• 1.8 Regional Market: Cagr Calculation
• 1.9 Research Assumptions
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations
• 1.12 Objectives
  • 1.12.1 Objective 1
  • 1.12.2 Objective 2

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Drug Class And Disease Condition Segment Snapshot
• 2.3 Distribution Chanel Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Global Gout Therapeutics Market Variables, Trends, & Scope

• 3.1 Gout Therapeutics Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Regulatory Framework
• 3.4 Market Driver Analysis
  • 3.4.1 Rising Prevalence Of Gout
  • 3.4.2 Advanced And New Therapies With Strong R&D Pipeline
  • 3.4.3 Rising Awareness Among People
• 3.5 Market Restraint Analysis
  • 3.5.1 Delayed Disease Diagnosis In Developing And Underdeveloped Countries
• 3.6 Porter's Five Forces Analysis
• 3.7 Pipeline Analysis

Chapter 4 Gout Therapeutics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

• 4.1 Global Gout Therapeutics Market: Drug Class Movement Analysis
• 4.2. Nsaids
  • 4.2.1. Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.3. Corticosteroids
  • 4.3.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.4. Colchicine
  • 4.4.1 Colchicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.5. Urate-Lowering Agents
  • 4.5.1 Urate-Lowering Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Gout Therapeutics - Segment Analysis, By Disease Condition, 2018 - 2030 (USD Million)

• 5.1. Global Gout Therapeutics Market: Disease Condition Movement Analysis
• 5.2. Acute Gout
  • 5.2.1. Acute Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.3. Chronic Gout
  • 5.3.1. Chronic Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Gout Therapeutics Market- Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

• 6.1. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
• 6.2. Hospital Pharmacy
  • 6.2.1. Hospital Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.3. Retail Pharmacy
  • 6.3.1. Retail Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.4. Online Pharmacy
  • 6.4.1. Online Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Gout Therapeutics Market: - Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Gout Therapeutics Market: Regional Movement Analysis
  • 7.1.1 Definition & Scope
• 7.2 North America
  • 7.2.1 North America, Swot Analysis
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Target Disease Prevalence
    • 7.2.2.4 Competitive Scenario
    • 7.2.2.5 Regulatory Framework
    • 7.2.2.6 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Target Disease Prevalence
    • 7.2.3.4 Competitive Scenario
    • 7.2.3.5 Regulatory Framework
    • 7.2.3.6 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe, Swot Analysis
  • 7.3.2 Uk
    • 7.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Target Disease Prevalence
    • 7.3.2.4 Competitive Scenario
    • 7.3.2.5 Regulatory Framework
    • 7.3.2.6 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Target Disease Prevalence
    • 7.3.3.4 Competitive Scenario
    • 7.3.3.5 Regulatory Framework
    • 7.3.3.6 Reimbursement Scenario
  • 7.3.4 France
    • 7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Target Disease Prevalence
    • 7.3.4.4 Competitive Scenario
    • 7.3.4.5 Regulatory Framework
    • 7.3.4.6 Reimbursement Scenario
  • 7.3.5 Italy
    • 7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Target Disease Prevalence
    • 7.3.5.4 Competitive Scenario
    • 7.3.5.5 Regulatory Framework
    • 7.3.5.6 Reimbursement Scenario
  • 7.3.6 Spain
    • 7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Target Disease Prevalence
    • 7.3.6.4 Competitive Scenario
    • 7.3.6.5 Regulatory Framework
    • 7.3.6.6 Reimbursement Scenario
  • 7.3.7 Sweden
    • 7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Target Disease Prevalence
    • 7.3.7.4 Competitive Scenario
    • 7.3.7.5 Regulatory Framework
    • 7.3.7.6 Reimbursement Scenario
  • 7.3.8 Denmark
    • 7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Target Disease Prevalence
    • 7.3.8.4 Competitive Scenario
    • 7.3.8.5 Regulatory Framework
    • 7.3.8.6 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Target Disease Prevalence
    • 7.3.9.4 Competitive Scenario
    • 7.3.9.5 Regulatory Framework
    • 7.3.9.6 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific, Swot Analysis
  • 7.4.2 India
    • 7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Target Disease Prevalence
    • 7.4.2.4 Competitive Scenario
    • 7.4.2.5 Regulatory Framework
    • 7.4.2.6 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Target Disease Prevalence
    • 7.4.3.4 Competitive Scenario
    • 7.4.3.5 Regulatory Framework
    • 7.4.3.6 Reimbursement Scenario
  • 7.4.4 Japan
    • 7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Target Disease Prevalence
    • 7.4.4.4 Competitive Scenario
    • 7.4.4.5 Regulatory Framework
    • 7.4.4.6 Reimbursement Scenario
  • 7.4.5 Australia
    • 7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Target Disease Prevalence
    • 7.4.5.4 Competitive Scenario
    • 7.4.5.5 Regulatory Framework
    • 7.4.5.6 Reimbursement Scenario
  • 7.4.6 South Korea
    • 7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Target Disease Prevalence
    • 7.4.6.4 Competitive Scenario
    • 7.4.6.5 Regulatory Framework
    • 7.4.6.6 Reimbursement Scenario
  • 7.4.7 Thailand
    • 7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Target Disease Prevalence
    • 7.4.7.4 Competitive Scenario
    • 7.4.7.5 Regulatory Framework
    • 7.4.7.6 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America, Swot Analysis
  • 7.5.2 Mexico
    • 7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Target Disease Prevalence
    • 7.5.2.4 Competitive Scenario
    • 7.5.2.5 Regulatory Framework
    • 7.5.2.6 Reimbursement Scenario
  • 7.5.3 Brazil
    • 7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Target Disease Prevalence
    • 7.5.3.4 Competitive Scenario
    • 7.5.3.5 Regulatory Framework
    • 7.5.3.6 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.4.2 Key Country Dynamics
    • 7.5.4.3 Target Disease Prevalence
    • 7.5.4.4 Competitive Scenario
    • 7.5.4.5 Regulatory Framework
    • 7.5.4.6 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 Middle East & Africa, Swot Analysis
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Target Disease Prevalence
    • 7.6.2.4 Competitive Scenario
    • 7.6.2.5 Regulatory Framework
    • 7.6.2.6 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Target Disease Prevalence
    • 7.6.3.4 Competitive Scenario
    • 7.6.3.5 Regulatory Framework
    • 7.6.3.6 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Target Disease Prevalence
    • 7.6.4.4 Competitive Scenario
    • 7.6.4.5 Regulatory Framework
    • 7.6.4.6 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Target Disease Prevalence
    • 7.6.5.4 Competitive Scenario
    • 7.6.5.5 Regulatory Framework
    • 7.6.5.6 Reimbursement Scenario

Chapter 8 Competitive Landscape

• 8.1 Public Companies
  • 8.1.1 Company Market Position Analysis
  • 8.1.2 Competitive Dashboard Analysis
  • 8.1.3 Strategic Framework
• 8.2 Private Companies
  • 8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
  • 8.2.2 Regional Network Map
• 8.3 Company Profiles
  • 8.3.1 Takeda Pharmaceutical Company Ltd.
    • 8.3.1.1 Company Overview
    • 8.3.1.2 Financial Performance
    • 8.3.1.3 Product Benchmarking
    • 8.3.1.4 Strategic Initiatives
  • 8.3.2 Novartis Ag
    • 8.3.2.1 Company Overview
    • 8.3.2.2 Financial Performance
    • 8.3.2.3 Product Benchmarking
    • 8.3.2.4 Strategic Initiatives
  • 8.3.3 Regeneron Pharmaceuticals Inc.
    • 8.3.3.1 Company Overview
    • 8.3.3.2 Financial Performance
    • 8.3.3.3 Product Benchmarking
    • 8.3.3.4 Strategic Initiatives
  • 8.3.4 Astrazeneca Plc
    • 8.3.4.1 Company Overview
    • 8.3.4.2 Financial Performance
    • 8.3.4.3 Product Benchmarking
    • 8.3.4.4 Strategic Initiatives
  • 8.3.5 Horizon Therapeutics Plc
    • 8.3.5.1 Company Overview
    • 8.3.5.2 Financial Performance
    • 8.3.5.3 Product Benchmarking
    • 8.3.5.4 Strategic Initiatives
  • 8.3.6 Merck & Co. Inc
    • 8.3.6.1 Company Overview
    • 8.3.6.2 Financial Performance
    • 8.3.6.3 Product Benchmarking
    • 8.3.6.4 Strategic Initiatives
  • 8.3.7 Zydus Group
    • 8.3.7.1 Company Overview
    • 8.3.7.2 Financial Performance
    • 8.3.7.3 Product Benchmarking
    • 8.3.7.4 Strategic Initiatives
  • 8.3.8 Teijin Ltd
    • 8.3.8.1 Company Overview
    • 8.3.8.2 Financial Performance
    • 8.3.8.3 Product Benchmarking
    • 8.3.8.4 Strategic Initiatives
  • 8.3.9 Glaxosmithkline Plc
    • 8.3.9.1 Company Overview
    • 8.3.9.2 Financial Performance
    • 8.3.9.3 Product Benchmarking
    • 8.3.9.4 Strategic Initiatives